NantKwest, Inc. (NK) Raised to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of NantKwest, Inc. (NASDAQ:NK) from a hold rating to a buy rating in a report published on Tuesday. Zacks Investment Research currently has $4.50 price objective on the biotechnology company’s stock.
According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
A number of other equities analysts have also recently issued reports on the stock. BidaskClub cut shares of NantKwest from a sell rating to a strong sell rating in a research note on Friday, September 22nd. Citigroup Inc. set a $3.00 price target on shares of NantKwest and gave the stock a sell rating in a research report on Monday, August 14th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $5.13.
Shares of NantKwest (NASDAQ NK) traded up $0.66 during trading on Tuesday, hitting $4.91. 522,612 shares of the company were exchanged, compared to its average volume of 375,280. NantKwest has a fifty-two week low of $2.71 and a fifty-two week high of $8.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47.
WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/17/nantkwest-inc-nk-raised-to-buy-at-zacks-investment-research.html.
In other NantKwest news, Director Steve Gorlin sold 39,604 shares of NantKwest stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $5.93, for a total value of $234,851.72. Following the sale, the director now directly owns 246,280 shares in the company, valued at approximately $1,460,440.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 70.19% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in NK. JPMorgan Chase & Co. boosted its holdings in shares of NantKwest by 155.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 25,579 shares of the biotechnology company’s stock worth $140,000 after buying an additional 71,444 shares during the period. SG Americas Securities LLC boosted its holdings in shares of NantKwest by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 49,356 shares of the biotechnology company’s stock worth $270,000 after buying an additional 35,424 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of NantKwest during the 3rd quarter worth about $139,000. California State Teachers Retirement System boosted its holdings in shares of NantKwest by 58.1% during the 2nd quarter. California State Teachers Retirement System now owns 54,154 shares of the biotechnology company’s stock worth $411,000 after buying an additional 19,900 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of NantKwest by 1,110.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,572 shares of the biotechnology company’s stock worth $210,000 after buying an additional 25,295 shares during the period. Institutional investors own 18.84% of the company’s stock.
NantKwest Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.